SAMHD1蛋白在经典型霍奇金淋巴瘤中为独立不良预后因素
在125例中位随访90个月的患者中,SAMHD1阳性与更差的FFP、DSS和OS显著相关。
要点
- SAMHD1阳性与更差的无进展生存、疾病特异性生存和总生存显著相关
- 多因素模型中SAMHD1表达对FFP、DSS和OS保持独立不良预后意义
核心结论
- SAMHD1在HRS细胞中的表达是经典型霍奇金淋巴瘤的独立不良预后因素。
研究设计与样本
- 回顾性队列研究,纳入154例接受标准方案治疗的霍奇金淋巴瘤患者。
- 用治疗前诊断性淋巴结活检行免疫组化检测SAMHD1,界值20%。
主要发现
- SAMHD1表达与年龄、性别、分期或组织学亚型等临床病理参数无关。
关键数值与推荐
- SAMHD1阳性判定界值为20%。
临床怎么用
- 治疗前活检可评估HRS细胞SAMHD1表达,辅助识别高危霍奇金淋巴瘤患者。
- SAMHD1抑制剂已可用于临床,提示该标志物可能具有治疗意义。
局限性
- 预后分析基于125例患者,非全部154例。
- 采用任意20%界值,SAMHD1阳性判定标准尚未统一。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The expression patterns and prognostic significance of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) protein in the neoplastic Hodgkin and Reed Sternberg (HRS) cells of Hodgkin lymphoma (HL) were investigated in a cohort of 154 patients with HL treated with standard regimens. SAMHD1 expression was assessed by immunohistochemistry using diagnostic lymph node biopsies obtained prior to treatment. Using an arbitrary 20% cut-off, SAMHD1 was positive in HRS cells of 48/154 (31·2%) patients. SAMHD1 expression was not associated with clinicopathologic parameters, such as age, gender, stage or histologic subtype. In 125 patients with a median follow-up of 90 months (7-401 months), SAMHD1 expression in HRS cells significantly correlated with inferior freedom from progression (FFP) (P = 0·025), disease-specific survival (DSS) (P = 0·013) and overall survival (OS) (P = 0·01). Importantly, in multivariate models together with disease stage, histology subtype and type of treatment as covariates, SAMHD1 expression retained an independent significant association with unfavourable FFP (P = 0·005) as well as DSS (P = 0·022) and OS (P = 0·018). These findings uncover the significance of a novel, adverse prognostic factor in HL that may have therapeutic implications since SAMHD1 inhibitors are now available for clinical use.
引用
- Xagoraris I, Vassilakopoulos TP, Drakos E, et al. Expression of the novel tumour suppressor sterile alpha motif and HD domain-containing protein 1 is an independent adverse prognostic factor in classical Hodgkin lymphoma. Br J Haematol. 2021. PMID: 33528031. doi:10.1111/bjh.17352
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。